Ursodeoxycholic acid ameliorates ibuprofen-induced enteropathy in the rat.

Abstract

BACKGROUND:

The objective of the study was to determine whether ursodeoxycholic acid (Ursodiol) is protective against ibuprofen (IBU)-induced enteropathy.

METHODS:

Using the chronically catheterized rat model, IBU (60 mg/kg body weight per day) was infused via the gastric catheter twice daily. Pancreatic enzyme (PE; 10,000 U lipase/kg body weight per day) and Ursodiol (10 mg/kg body weight per day) in two doses were infused via the duodenal catheter. Rats were assigned to one of six treatment groups and were administered treatment for 20 days: control, IBU, PE, IBU + PE, IBU + Ursodiol, and IBU + PE + Ursodiol. The entire jejunum, ileum, cecum, and colon were available for histologic analysis using previously described techniques.

RESULTS:

Addition of Ursodiol to high-dose IBU and normal doses of PE showed a significant reduction in the percentage of rats with ulcers (P < 0.05), total number of serositis events (P < 0.01), total number of severe ulcers (P < 0.001), and an absence of ulcers in the large intestine.

CONCLUSIONS:

Ursodiol, the drug of choice for the treatment of cystic fibrosis liver disease, may offer a safe method of using high-dose IBU in these patients by ameliorating the enteropathy.

• Authors: J D Lloyd-Still, D W Beno, M R Uhing, V A Jiyamapa-Serna, R E Kimura
• Journal: Journal of pediatric gastroenterology and nutrition (J Pediatr Gastroenterol Nutr) Vol. 32 Issue 3 Pg. 270-3 (Mar 2001) ISSN: 0277-2116 [Print] United States
• PMID: 11345174 (Publication Type: Journal Article)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Cholagogues and Choleretics
• Ursodeoxycholic Acid
• Lipase
• Ibuprofen

Topics

• Animals
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, toxicity)
• Catheterization
• Cholagogues and Choleretics (therapeutic use)
• Cystic Fibrosis (complications, drug therapy)
• Disease Models, Animal
• Ibuprofen (administration & dosage, toxicity)
• Intestinal Diseases (chemically induced, prevention & control)
• Intestines (drug effects, pathology)
• Lipase (administration & dosage)
• Male
• Random Allocation
• Rats
• Rats, Sprague-Dawley
• Serositis (chemically induced, prevention & control)
• Ulcer (chemically induced, prevention & control)
• Ursodeoxycholic Acid (therapeutic use)